Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies
SINGAPORE and SAN DIEGO – April 14, 2021 – ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced it has completed a $14 million fundraising round co-led by new investor EDBI together with existing investors Anzu Partners and University of Tokyo Edge Capital Partners (UTEC).
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed that the Company concluded an agreement with the Ministry of Health of Singapore to supply mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support ongoing efforts to secure access to a safe and effective COVID-19 vaccine for the people of Singapore.
SINGAPORE – 31 March 2020 – Doctor Anywhere , a regional tech-led healthcare company headquartered in Singapore, announced today that it has secured a US$27 million Series B financing round led by Square Peg – the largest venture capital fund in Australia, Singapore Government investment arm – EDBI, and IHH Healthcare, a leading international healthcare provider. Rounding out this series of funding are Pavilion Capital and existing shareholder Kamet Capital, bringing Doctor Anywhere’s total capital base to exceed US$40 million.